#
AstraZeneca# and #
IonisPharmaceutical# are the first to receive FDA approval for the #
antisenseoligonucleotide# (ASO) based RNA drug #
eplontersen#.
The only treatment for the treatment of PN transthyretin-mediated amyloidosis (hATTR-PN).
.
#
RNAtherapeutics#
.